BB-201, a potent first-in-class anti-Her2/anti-Trop2 bispecific ADC candidate

Nov. 19, 2024

Researchers from Bright Biologics LLC presented the discovery and preclinical characterization of a novel bispecific anti-Her2/anti-Trop2 antibody-drug conjugate (ADC), BB-201.

BioWorld Science Conferences Society for Immunotherapy of Cancer Cancer Antibody-drug conjugate

Today's news in brief

BioWorld

BioWorld briefs for Jan. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 31, 2025

Vilastobart set apart? Xilio phase II combo performs in CRC

BioWorld

“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...

Novo weight-loss data roll out; Veru ‘leans’ in

BioWorld

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line...

Appointments and advancements for Jan. 29, 2025

BioWorld

New hires and promotions in the biopharma industry, including: Allogene, Alumis, Beximco, Clarametyx, Commit, Concerto, OS Therapies, Precision, Roche, Scholar Rock.